静脉泊沙康唑治疗重症侵袭性肺曲霉病的给药方案:群体药代动力学建模与模拟研究
基于POSA-FLU药代动力学亚组31例患者532个血药浓度建立群体药代动力学模型,模拟评估静脉泊沙康唑治疗重症侵袭性肺曲霉病的达标概率。优化负荷方案为体重<100 kg者300 mg q12h、≥100 kg者300 mg q8h,维持400 mg q24h可使Cmin达标概率≥90%,标准300 mg q24h可维持AUC0-24达标。
要点
- 负荷方案:体重<100 kg予300 mg q12h,≥100 kg予300 mg q8h,均于治疗前2天给药
- 维持400 mg q24h可使Cmin达标概率≥90%,标准300 mg q24h可维持AUC0-24达标
- 达标概率≥90%被视为临床可接受
核心结论
- 本研究定义了一种便捷的优化静脉泊沙康唑给药方案,预测可在重症侵袭性曲霉病患者中达到治疗目标。
研究设计与样本
- 基于POSA-FLU药代动力学亚组(NCT03378479)数据建立群体药代动力学模型,采用蒙特卡洛模拟评估Cmin和AUC0-24的达标概率,模拟使用NONMEM 7.5。
- 药代动力学亚组纳入31例接受密集药代动力学采样的患者,贡献532个泊沙康唑血浆浓度。
主要发现
- 静脉泊沙康唑群体药代动力学最佳描述为二室模型,线性消除。
- 清除率及中央和外周室分布容积存在个体间变异。
- 泊沙康唑外周室分布容积随体重增加。
- 体重<100 kg患者前2天予300 mg q12h、≥100 kg患者予300 mg q8h的优化负荷方案,至第3天达标概率可接受。
- 维持方案400 mg q24h可使Cmin达标概率≥90%,而标准300 mg q24h在14天内可达到AUC0-24目标,与体重无关。
关键数值与推荐
- prophylaxis Cmin目标为0.7 mg/L,治疗Cmin目标为1.0 mg/L。
- 达标概率≥90%被视为临床可接受。
- 优化负荷方案:体重<100 kg者300 mg q12h,体重≥100 kg者300 mg q8h,均于治疗前2天给药。
- 维持方案:400 mg q24h可使Cmin达标概率≥90%;标准300 mg q24h可达到AUC0-24目标。
临床怎么用
- 作者提出了一种便捷的优化静脉泊沙康唑给药方案,预测可在重症侵袭性曲霉病患者中达到治疗目标。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Posaconazole is used for the prophylaxis and treatment of invasive fungal infections in critically ill patients. Standard dosing was shown to result in adequate attainment of the prophylaxis Cmin target (0.7 mg/L) but not of the treatment Cmin target (1.0 mg/L). OBJECTIVES: To provide an optimized posaconazole dosing regimen for IV treatment of patients with invasive pulmonary aspergillosis in the ICU. METHODS: A population pharmacokinetics (popPK) model was developed using data from the POSA-FLU PK substudy (NCT03378479). Monte Carlo simulations were performed to assess treatment Cmin and AUC0-24 PTA. PTA ≥90% was deemed clinically acceptable. PopPK modelling and simulation were performed using NONMEM 7.5. RESULTS: Thirty-one patients with intensive PK sampling were included in the PK substudy, contributing 532 posaconazole plasma concentrations. The popPK of IV posaconazole was best described by a two-compartment model with linear elimination. Interindividual variability was estimated on clearance and volume of distribution in central and peripheral compartments. Posaconazole peripheral volume of distribution increased with bodyweight. An optimized loading regimen of 300 mg q12h and 300 mg q8h in the first two treatment days achieved acceptable PTA by Day 3 in patients <100 kg and ≥100 kg, respectively. A maintenance regimen of 400 mg q24h ensured ≥90% Cmin PTA, whereas the standard 300 mg q24h was sufficient to achieve the AUC0-24 target throughout 14 days, irrespective of bodyweight. CONCLUSIONS: We have defined a convenient, optimized IV posaconazole dosing regimen that was predicted to attain the treatment target in critically ill patients with invasive aspergillosis.
引用
- Elkayal O, Mertens B, Wauters J, et al. Dosing of IV posaconazole to treat critically ill patients with invasive pulmonary aspergillosis: a population pharmacokinetics modelling and simulation study. J Antimicrob Chemother. 2024. PMID: 38828958. doi:10.1093/jac/dkae160
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。